Clinical Study of Ursodeoxycholic Acid Combined with Reduced Glutathione for Fatty Liver Disease

OBJECTIVE: To observe the clinical efficacy and safety of ursodeoxycholic acid combined with reduced glutathione for fatty liver disease. METHODS: 79 patients with fatty liver were randomly divided into 2 groups: 40 patients in therapy group were treated with oral dose of Ursodeoxycholic acid capsules 0.25 g and Reduced glutathione tablets 0.2 g three times a day for 3 months, and 39 in control group treated with oral dose of Ursodeoxycholic acid capsules in the same period. Clinical symptom, hepatic function, blood lipid and adverse drug reaction were observed. RESULTS: The total effective rate of therapy group (92.50%) was higher than that of control group (76.92%), there was statistical significance (P0.05). After treatment, hepatic function of 2 groups were decreased significantly, there was statistical significance (therapy group: P0.01; control group: P0.05). The level of blood lipid of 2 groups were also decreased significantly (P0.01). Compared with control group, liver function and blood lipids of therapy group reduced significantly(P0.05). No obvious adverse drug reaction was found during treatment. CONCLUSION: Ursodeoxycholic acid is effective in the treatment of fatty liver disease. Ursodeoxycholic acid combined with reduced glutathione can improve clinical efficacy significantly with sound safety and without obvious adverse drug reaction.